Citations of our work in Google Scholar
2017
Leroy, B., Ballinger, M. L., Baran-Marszak, F., Bond, G. L., Braithwaite, A., Concin, N., Donehower, L. A., El-Deiry, W. S., Fenaux, P., Gaidano, G., Langerød, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P. L., Malkin, D., Moll, U. M., Myers, J. N., Nichols, K. E., Pospisilova, S., Ashton-Prolla, P., Rossi, D., Savage, S. A., Strong, L. C., Tonin, P. N., Zeillinger, R., Zenz, T., Fraumeni, J. F., Taschner, P. E., Hainaut, P., and Soussi, T. (2017). Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 6, 1250-1260. LINK (open access)
Soussi, T., and Kroemer, G. (2016). TP53 and 53BP1 Reunited. Trends Cell Biol in press
2016
Soussi, T., Taschner, P. E., and Samuels, Y. (2017). Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications. Hum Mutat 38, 339-342.
Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F (2016) TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer, 139: 1759–1763; PDF LINK
Lodé L, Cymbalista F, Soussi T (2016) Genetic profiling of CLL: a 'TP53 addict' perspective. Cell Death Dis, 7: e2042; PDF; LINK
2015
Soussi T, Wiman KG (2015) TP53: an oncogene in disguise. Cell Death Differ, 22: 1239–1249; PDF; LINK
2014
Soussi T (2014) The TP53 Gene Network in a Post-Genomic Era. Hum Mutat, 35: 641–642; PDF; LINK
Soussi T (2014) Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB Paradigm. Hum Mutat, 35: 643–653; PDF; LINK
Leroy B, Anderson M & Soussi T (2014) TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Hum Mutat, 35: 672–688; PDF; LINK
Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF & Soussi T (2014) Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment. Hum Mutat, 35: 756–765; PDF; LINK
Soussi T, Leroy B & Taschner PE (2014) Recommendations for Analyzing and Reporting TP53 Gene Variants in the High-Throughput Sequencing Era. Hum Mutat, 35: 766–778; PDF; LINK
2013
Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G & Soussi T (2013) The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res, 41: D962–D969 ; PDF; LINK
2012
Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundstrom M, Micke P, Botling J & Soussi T (2012) Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A, 109: 9551–9556 PDF; LINK
2011
Soussi T (2011) TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Adv Cancer Res, 110: 107–139 PDF; LINK
Soussi T (2011) Advances in carcinogenesis: A historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. Biochim Biophys Acta, 1816: 199–208 PDF; LINK
2010
Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Habe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Dohner H & Stilgenbauer S (2010) TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24: 2072–2079 PDF; LINK
Soussi T, Hamroun D, Hjortsberg L, Rubio-Nevado JM, Fournier JL & Beroud C (2010) MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat, 31: 1020–1025 PDF; LINK
Lode L, Eveillard M, Trichet V, Soussi T, Wuilleme S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traulle C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S & Avet-Loiseau H (2010) Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica, 95: 1973–1976 PDF LINK
Soussi T (2010) The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep, 11: 822–826 PDF; LINK
2009
Carlsson J, Soussi T & Persson B (2009) Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. FEBS J, 276: 4142–4155 PDF; LINK
Soussi T & Hjortsberg L (2009) When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy? Trends Mol Med, 15: 1–4 PDF; LINK
2008
Berglind H, Pawitan Y, Kato S, Ishioka C & Soussi T (2008) Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther, 7: 699–708 PDF LINK
Soussi Zander C & Soussi T (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med, 358: 1635; author reply 1636 PDF; LINK
Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T & Kroemer G (2008) Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle, 7: 3056–3061 PDF; LINK
2007
Soussi T (2007) p53 alterations in human cancer: more questions than answers. Oncogene, 26: 2145–2156 PDF; LINK
Soussi T & Wiman KG (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell, 12: 303–312 PDF; LINK
Ren ZP, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A & Nister M (2007) Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol, 66: 944–954 PDF; LINK